biotechs

The more advanced the development, the better the financial terms biotechs are likely to get from the large pharmaceutical companies.

Biotech Embraces A Financial LifelineBiotech's Financial Lifeline 2006

Elsevier projects there will be roughly 100 link-ups this year between big firms and small biotechs over the pre-clinical assets.

Abbott Labs Licenses Molecules from Reata Jonathan D. Rockoff 2011

The pharmaceutical industry as a whole has spent more than $130 billion acquiring small biotechs since 2006.

Drug Makers Refill Parched Pipelines Jonathan D. Rockoff 2011

"With the changing model of pharmaceutical companies, we anticipate a great proportion of our spend will be in collaboration with biotechs and academia," he says.

R&D Cuts Curb Brain-Drug Pipeline 2011

"It is not just the risky, nimble biotechs that are developing these novel agents," said Ms. Belvin's doctor, Jedd Wolchok of Memorial Sloan-Kettering Cancer Center in New York.

Drug Makers Refill Parched Pipelines Jonathan D. Rockoff 2011

Spreading Some BioVex Magic Amgen Inc. paid an amazing price for BioVex Inc., one that's sure to spark deal interest in other biotechs working on anticancers that act in a similar way.

Espirito Santo's Surprise Loan Move 2011

A biotechnology analyst in New York said that the SEC and other financial-system regulators have been asking more questions of banking firms regarding the underwriting of smaller biotechs with lower-price stock, the kinds of companies in which Mr. Liang allegedly traded.

Insider-Trading Case Puts Focus on Key FDA System Alicia Mundy 2011

The collapse underscores the challenges for the many collaborations that big drug makers have been striking with smaller biotechs to spur innovation while reducing their risks.

Amylin, Lilly End Ill-Fated Linkup Jonathan D. Rockoff 2011

Tie-ups between Big Pharma and small biotechs aren't uncommon, but this deal is unusual in that larger drug makers have been loath to sign up at such an unproven, early stage.

Pfizer, Biotech Partner to Develop Drugs for Rare Diseases Jonathan D. Rockoff 2011

Treating hepatitis C is a popular area for drug development at both biotechs and larger pharmaceutical companies, something that could bring a crop of new products in coming years.

Hepatitis C Drug Approved Thomas Gryta 2011